8-K: Vycor Medical Reports Strong Q3 Growth, Operating Profit Surges

Vycor Medical, Inc. announced significant revenue growth and a return to operating profit for the three and nine months ended September 30, 2025, driven by its Vycor Medical division.

Summary

• Total revenue for the three months ended September 30, 2025, increased by 31% to $513,792 compared to $390,852 in the prior year.
• Total revenue for the nine months ended September 30, 2025, increased by 28% to $1,446,523 compared to $1,134,098 in the prior year.
• The Vycor Medical division (VBAS) saw revenue increase by 32% for the three months and 29% for the nine months, reaching $492,102 and $1,392,410 respectively.
• Operating profit for the three months was $32,085 (GAAP) and $60,162 (non-GAAP), a substantial increase from operating losses in 2024.
• Operating profit for the nine months was $70,425 (GAAP) and $166,262 (non-GAAP), also a significant improvement over 2024.
• Net loss available to common stockholders decreased to $(157,249) (GAAP) and $(129,172) (non-GAAP) for the three months, and to $(334,110) (GAAP) and $(238,273) (non-GAAP) for the nine months.
• Three new clinical papers involving the ViewSite Brain Access System (VBAS) were published in Q3 2025, bringing the total to 50 peer-reviewed papers.
• A new clinical study on NovaVision's NeuroEyeCoach validated its effectiveness for both home-based and clinic-based use.

Sentiment

Score: 8

Explanation: The company demonstrated strong revenue growth and a significant turnaround in operating profitability, coupled with positive clinical developments and strategic market expansion. While net losses persist and gross margins slightly declined, the overall trend is highly positive, indicating improved operational performance and market acceptance of its products.

Positives

• Total revenue increased by 31% for the three months and 28% for the nine months ended September 30, 2025.
• The Vycor Medical division (VBAS) achieved 32% revenue growth in Q3 and 29% for the nine months, with significant growth in international markets for the nine-month period, aligning with a key strategic objective.
• The company returned to GAAP operating profit of $32,085 for the three months and $70,425 for the nine months, a substantial improvement from losses in the prior year.
• Non-GAAP operating profit showed even stronger performance, reaching $60,162 for the three months and $166,262 for the nine months.
• Net losses available to common stockholders significantly decreased compared to the prior year periods.
• Three new clinical papers on VBAS were published in Q3, including a multi-center study showing promising results for deep intracerebral hemorrhage evacuation with shorter patient length of stay.
• A new clinical study validated NovaVision's NeuroEyeCoach as an effective tool for visual rehabilitation in both home and clinic settings, supporting the drive for digital healthcare technologies.

Negatives

• Gross profit margin for the Vycor Medical division decreased to 88% for the three months and 84% for the nine months in 2025, down from 90% in 2024, primarily due to validation and shipping costs of new production runs and higher international sales mix.
• The NovaVision division, while showing positive clinical study results, remains 'in development' and its therapies 'still require significant development to allow them to successfully address their market potential.'
• NovaVision's revenue for the nine months ended September 30, 2025, slightly decreased to $54,113 from $55,454 in 2024.
• The company continues to report a net loss available to common stockholders, despite improvements in operating profit.

Risks

• Known and unknown risks, uncertainties, and other factors could cause actual results, performance, or achievements to differ from forward-looking statements.
• The company's operating results can be impacted by the timing and magnitude of acquisitions, affecting non-cash depreciation charges.
• Stock-based compensation expenses, due to varying valuation methodologies and subjective assumptions, can impact operating results and may not be accurately comparable across periods.

Future Outlook

The company's NovaVision division therapies 'still require significant development to allow them to successfully address their market potential,' indicating future investment and strategic focus on this segment. The company also aims for continued international market growth for its Vycor Medical division.

Management Comments

• The Vycor Medical division's revenue increase for the nine months was primarily from international markets, which is a key strategic objective.
• The multi-center study on VBAS for deep intracerebral hemorrhage evacuation suggests that the use of Vycor tubular retractors is promising, leading to a shorter length of stay for patients post-surgery than existing methods.
• The new clinical study on NovaVision's NeuroEyeCoach validates it as an effective tool, whether used clinically or accessed remotely, which is important given the significant drive in healthcare systems worldwide to access digital technologies in home settings.

Industry Context

The company's focus on international market expansion for its neurosurgical device (VBAS) aligns with the global growth in medical device markets. The validation of NovaVision's NeuroEyeCoach for home-based use positions the company to capitalize on the broader healthcare trend towards digital health technologies and remote patient care, especially for neurological rehabilitation post-stroke or brain injury.

Comparison to Industry Standards

• The ViewSite Brain Access System (VBAS) is FDA-cleared and used in over 350 hospitals in the US and internationally, suggesting a strong market presence within its niche of minimally invasive neurosurgery.
• VBAS is protected by 48 issued and 9 pending patents and has been validated through 50 peer-reviewed studies, indicating a robust intellectual property portfolio and strong clinical evidence, which are critical for competitive advantage in the medical device industry.
• NovaVision's Visual Restoration Therapy (VRT) is highlighted as the 'only commercialized FDA-cleared therapy for vision rehabilitation following neurological brain damage,' positioning it as a unique offering in the neuro-visual space, though its market potential still requires significant development.
• The NeuroEyeCoach program's 296-patient study is noted as 'the largest to date in the neuro visual space,' providing substantial clinical backing for its efficacy compared to other programs in this emerging field.

Related Party Transactions

• Interest expense: Related Party of $(12,571) for the three months and $(37,713) for the nine months ended September 30, 2025.

Stakeholder Impact

• Shareholders: Positive impact due to significant revenue growth, improved operating profit, and reduced net losses, suggesting a stronger financial position and potential for future value creation.
• Customers (hospitals, neurosurgeons, patients): Positive impact through continued clinical validation of VBAS leading to improved patient outcomes (e.g., shorter length of stay) and the validation of NovaVision's NeuroEyeCoach for accessible, effective visual rehabilitation.
• Employees: Positive impact from a growing company with expanding operations and product development, potentially leading to increased stability and opportunities.
• Creditors: The reduction in net losses and improved operating profit may signal a stronger ability to meet financial obligations, potentially improving creditworthiness.

Next Steps

• Continue significant development for NovaVision therapies to address their market potential.
• Further expand the Vycor Medical division's presence in international markets.
• Monitor the impact of validation and shipping costs on gross profit margins for new production runs.

Key Dates

Recommendation

The filing indicates a strong operational turnaround with significant revenue growth in both the Vycor Medical and NovaVision divisions, coupled with a return to operating profitability. The substantial reduction in net losses, positive clinical study results for both VBAS and NeuroEyeCoach, and strategic expansion into international markets demonstrate robust progress. While gross margins saw a slight dip due to growth-related costs, the overall trajectory suggests increasing market adoption and improved financial health. The unique FDA-cleared status of VRT and extensive patent protection for VBAS provide a strong competitive moat. These factors collectively point to a company executing well on its strategy, making it an attractive 'buy' for investors seeking growth in the medical technology sector.

Keywords

Vycor Medical, VBAS, NovaVision, NeuroEyeCoach, neurosurgery, brain access system, visual rehabilitation, stroke recovery, brain injury, medical devices, financial results, operating profit, revenue growth, clinical studies, Q3 2025, OTCQB: VYCO